Researchers find new method of fixing broken proteins to treat genetic diseases

Jan 15, 2010

Researchers at Fox Chase Cancer Center have demonstrated how it could be possible to treat genetic diseases by enhancing the natural ability of cells to restore their own mutant proteins. In particular, they found that drugs called proteosome inhibitors could provide one way of manipulating cells into producing more of a so-called chaperone protein, named Hsp70, which helps amino acid chains fold into their proper protein form.

Their latest findings, presented in the journal , expand their previous research from yeast models of disease to human cell cultures and animal models. According to the researchers, if this approach works in humans, it could be a way to turn certain debilitating - or even fatal - genetic diseases into more treatable, chronic conditions.

"Hsp70 pulls misfolded mutant proteins apart like a twisted rubber bands and allows them to snap back into place, eventually a significant percentage of these proteins will snap back into something approaching a functional shape," says the study's leader, Warren Kruger, Ph.D., professor in Fox Chase's Cancer Biology program. "If this can be done in humans, it could represent a way of reducing the severity - or perhaps correcting - certain hereditary diseases, even some familial cancers."

Genetic diseases are often caused by a specific type of called a missense mutation that makes cells add an incorrect amino acid into the protein chain. Since the shape of a protein depends on the specific arrangement of , even a single error amid a gene's very long stretch of DNA can cause the gene's protein product to become misshapen. Kruger and his colleagues studied ways to reverse the functional effects of missense mutationsfor three : two severe inherited metabolic disorders (CBS deficiency and MTHFR deficiency) and one inherited cancer syndrome (Li-Fraumeini).

In each case, the Fox Chase researchers found that it was possible to restore the function of the mutant proteins by tricking the cell into increasing levels of Hsp70. "We have shown that the more opportunities we give Hsp70 proteins to try to 'fix' mutants, the more likely it is that they will succeed," Kruger says.

While this approach has yet to be applied to clinical medicine, there are several drugs that are known to induce Hsp70 in humans. Kruger found that treating yeast and mammalian cells with a drug called bortezomib elevated the amount of available Hsp70 and rescued mutant proteins. Bortezomib is a member of a class of drugs called proteasome inhibitors, which decreases the effectiveness of enzymes that cells use to dispose of non-functioning proteins. Bortezemib (known under the brand name Velcade) is currently used to treat patients with multiple myeloma.

"We found that bortezomib can stabilize and restore mutants by tripling the amount of available Hsp70," Kruger says. "While we do not yet know the entiremechanism, we do know that bortezomib doesn't rescue mutants in cells that lack the gene for Hsp70."

Kruger and his colleagues are currently studying how to best adapt these findings to human disease.

"Of course, the big question we need to answer is one of safety - what are the long term effects of sustained Hsp70 elevation?" Kruger says. "The answer may be very disease-specific, one of how many mutant proteins must be restored to reduce the severity of a given genetic disease."

Explore further: Down's chromosome cause genome-wide disruption

add to favorites email to friend print save as pdf

Related Stories

Researchers give mutants another chance

Feb 11, 2009

Researchers at Fox Chase Cancer Center have demonstrated that it might be possible to treat genetic diseases, including some forms of cancer, by "rescuing" the misshapen, useless proteins produced by some mutant genes.

Protein inhibitor helps rid brain of toxic tau protein

Sep 29, 2009

Inhibiting the protein Hsp70 rapidly reduces brain levels of tau, a protein associated with Alzheimer's disease when it builds up abnormally inside nerve cells affecting memory, neuroscientists at the University ...

Physics and biology team up to tackle protein folding debate

Apr 04, 2006

A team of researchers from EPFL, (Ecole Polytechnique Fédérale de Lausanne), the University of Lausanne, Northwestern University and Tel Aviv University bring biology and statistical physics together to answer the question ...

Recommended for you

Down's chromosome cause genome-wide disruption

5 minutes ago

The extra copy of Chromosome 21 that causes Down's syndrome throws a spanner into the workings of all the other chromosomes as well, said a study published Wednesday that surprised its authors.

Research uncovers DNA looping damage tied to HPV cancer

6 hours ago

It's long been known that certain strains of human papillomavirus (HPV) cause cancer. Now, researchers at The Ohio State University have determined a new way that HPV might spark cancer development – by ...

New therapy against rare gene defects

Apr 15, 2014

On 15th April is the 1st International Pompe Disease Day, a campaign to raise awareness of this rare but severe gene defect. Pompe Disease is only one of more than 40 metabolic disorders that mainly affect children under ...

User comments : 0

More news stories

Researchers see hospitalization records as additional tool

Comparing hospitalization records with data reported to local boards of health presents a more accurate way to monitor how well communities track disease outbreaks, according to a paper published April 16 in the journal PLOS ON ...

Ebola virus in Africa outbreak is a new strain

Scientists say that the Ebola (ee-BOH'-lah) virus that has killed scores of people this year in Guinea (GIH'-nee) is a new strain. That means it did not spread there from outbreaks in some other African nations.